Researchers at the Lady Davis Institute have identified a key protein that is required for resistance to chemotherapy in the most aggressive form of breast cancer. This holds the promise of opening the door to new therapies for overcoming drug resistance.
Montreal, December 2, 2019 – Using tumor biopsies from patients with chemotherapeutic resistant triple negative breast cancer (TNBC), researchers at the Lady Davis Institute of the Jewish General Hospital (JGH) have identified changes to the form of the cancer cells that appear to be associated with their capacity to resist usual drug treatment. This discovery is featured on the cover of the December issue of Molecular Cancer Research, where it is highlighted for its importance.
See attachment for more details.